**Name of Journal: *World Journal of Hepatology***

**Manuscript NO: 33640**

**Manuscript Type: Review**

**Value of quality of life analysis in liver cancer: A clinician’s perspective**

Li L *et al*. Quality of life in hepatocellular carcinoma

**Leung Li, Winnie Yeo**

**Leung Li, Winnie Yeo,** Department of Clinical Oncology, Prince of Wales Hospital, Faculty of Medicine, the Chinese University of Hong Kong, Hong Kong, China

**Author contributions:** All authors equally contributed to this paper with conception and design of the study, literature review and analysis, drafting and critical revision and editing, and final approval of the final version.

**Conflict-of-interest statement:** No potential conflicts of interest. No financial support.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Correspondence to:** **Winnie Yeo, MBBS (Lond), AKC (Lond), FHKCP(HK), FHKAM(HK), FRCP (Lond), FRCP (Edin), Professor,** Department of Clinical Oncology, Prince of Wales Hospital, Faculty of Medicine, the Chinese University of Hong Kong, Shatin, NT, Hong Kong, China. winnieyeo@cuhk.edu.hk

**Telephone:** +852-26322118

**Fax:** +852-26487097

**Received:** February 21, 2017

**Peer-review started:** February 26, 2017

**First decision:** March 29, 2017

**Revised:** May 15, 2017

**Accepted:** May 22, 2017

**Article in press:**

**Published online:**

**Abstract**

Health related quality of life (HRQOL) is increasingly recognized as an important clinical parameter and research endpoint in patients with hepatocellular carcinoma (HCC). HRQOL in HCC patients is multifaceted and affected by medical factor which encompasses HCC and its complications, oncological and palliative treatment for HCC, underlying liver disease, as well as the psychological, social or spiritual reaction to the disease. Many patients presented late with advanced disease and limited survival, plagued with multiple symptoms, rendering QOL a very important aspect in their general well being. Various instruments have been developed and validated to measure and report HRQOL in HCC patients, these included general HRQOL instruments, *e.g.*, Short Form 36 (SF-36), Short Form 12 (SF-12), EuroQoL-5D (EQ-5D), World Health Organization Quality of Life Assessment 100 (WHOQOL-100),World Health Organization Quality of Life Assessment abbreviated version (WHOQOL-BREF); general cancer HRQOL instruments, *e.g.*, the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30, Functional Assessment of Cancer Therapy - General (FACT-G), Spitzer Quality of Life Index (Spitzer QoL index); and liver-cancer specific HRQOL instruments, *e.g.*, EORTC QLQ-HCC18, FACT-Hepatobiliary (FACT-Hep), FACT-Hepatobiliary Symptom Index (FHSI-8), Trial Outcome Index (TOI). Important utilization of HRQOL in HCC patients included description of symptomatology and HRQOL of patients, treatment endpoint in clinical trial, prognostication of survival, benchmarking of palliative care service and health care valuation. In this review, difficulties regarding the use of HRQOL data in research and clinical practice, including choosing a suitable instrument, problems of missing data, data interpretation, analysis and presentation are examined. Potential solutions are also discussed.

**Key words:** Hepatocellular carcinoma; Health related quality of life; Palliative care; Prognosis; Survival; EORTC QLQ-C30; QLQ-HCC18; Index score; FACT; FHSI-8; EQ-5D; Spitzer; Short Form 36; WHOQOL

© **The Author(s) 2017**. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Health related quality of life (HRQOL) is an important clinical parameter and research endpoint in hepatocellular carcinoma (HCC) patients. Instruments discussed are SF-36, SF-12, EQ-5D, WHOQOL-100, WHOQOL-BREF, EORTC QLQ-C30, FACT-G, Spitzer QoL index, EORTC QLQ-HCC18, FACT-Hep, FHSI-8, TOI. Important utilization of HRQOL included measurement and monitoring of HRQOL, treatment endpoint in clinical trial, prognostication of survival, benchmarking of palliative care service and health care valuation. Various difficulties in using HRQOL data in research and clinical practice, including choosing a suitable instrument, missing data, data interpretation, analysis and presentation are explained. Potential solutions are also discussed.

Li L, Yeo W. Value of quality of life analysis in liver cancer: A clinician’s perspective. *World J Hepatol* 2017; In press

**INTRODUCTION**

Hepatocellular carcinoma (HCC) is a common and aggressive cancer that arises usually in a cirrhotic liver. Etiological pattern differs between Caucasians (mostly alcoholic liver disease and hepatitis C viral infection) and Asians (predominantly chronic hepatitis B)[1,2]. HCC carries high morbidity and mortality, since many patients present only when symptomatic. Patients with early disease are typically asymptomatic and their diseases are usually detected by regular HCC screening or incidental finding during investigation for other diseases[3]. Advanced disease at presentation is common and patients suffer from symptoms resulting from large space occupying lesion(s) in the liver or associated hepatic dysfunction/failure.

Early diseases are potentially curable by complete surgical extirpation[4,5]. Local tumor ablation, for example radiofrequency ablation (RFA), is a reasonable alternative to partial hepatectomy for small HCC[6,7]. Liver transplantation is considered if the disease falls within the Milan criteria but the anticipated residual liver function is not adequate[8]. Liver directed therapies, such as transarterial chemoembolisation (TACE) and selective internal radiation therapy (SIRT), are palliative treatment for patients with higher tumor burden that is confined to the liver[9-11]. For patients with advanced disease palliative treatment with systemic targeted agents, namely sorafenib and regorafenib, were demonstrated to improve their overall survival (OS)[12-14]. However, in the two phase III trials of first-line sorafenib in advanced HCC patients, the improvement in median OS was modest at 2-3 mo[12,13] when compared to placebo. Similar magnitude of benefit was observed in the second-line setting using regorafenib when compared to placebo[14].

In most clinical trials on patients with advanced HCC, the endpoints of interest are disease-free survival (DFS), progression-free survival (PFS) and OS. However in this poor prognostic group, treatment is mainly palliative and the survival benefit is modest. Hence, apart from survival improvement, health related quality of life (HRQOL) becomes very relevant. Thus, increasing number of phase III HCC trials have adopted QOL as additional study endpoints. HRQOL therefore has become an important monitoring parameter and treatment goal in clinical research and practice.

HRQOL in HCC patients is a complicated and multidimensional issue that involves medical, psychological, social and spiritual factors. Apart from symptoms arising from HCC and its complications, underlying liver disease and oncological treatment are intertwined with other factors including palliative care service, social and spiritual support, individual’s coping skill, patients’ function and general well being as well as cultural background, educational level and health literacy.

Therefore HRQOL intrinsically is a multifaceted and complex assessment of human life. Assessment of HRQOL should be comprehensive. Various instruments have been developed to measure and report HRQOL in these patients, they also serve as a means to communicate and reflect on patient’s overall well being.

**HRQOL INSTRUMENTS UTILIZED TO ASSESS HCC PATIENTS**

***HRQOL assessment using general tools***

HRQOL in HCC patients could be measured using general cancer QOL instruments, *e.g.*, the European Organization for Research and Treatment of Cancer QLQ-C30[15], Functional Assessment of Cancer Therapy – General[16], Spitzer Quality of Life Index[17]; as well as general disease QOL instruments, *e.g.*, Short Form 36[18], Short Form 12[19], World Health Organization Quality of Life Assessment 100[20],World Health Organization Quality of Life Assessment abbreviated version[21], EuroQoL-5D[22,23]. These are described in Table 2.

***HRQOL assessment using liver-cancer specific tools***

Since HCC patients commonly have symptoms related to concomitant underlying liver disease in addition to the tumor(s) within the liver, liver-cancer specific HRQOL instruments have been developed to address symptoms in relation to the malignancy as well as chronic liver disease. These include the European Organization for Research and Treatment of Cancer QLQ-HCC18[24], Functional Assessment of Cancer Therapy-Hepatobiliary[25], Functional Assessment of Cancer Therapy-Hepatobiliary Symptom Index[26] and Trial Outcome Index[25]. Liver specific tools are used together with their general counterparts. See Table 2 for description of each instrument.

***Validation of HRQOL instruments***

All the above instruments were validated, many were widely validated in patients of different languages and cultural backgrounds [15-17,19-21,25-30].

Validation of an HRQOL instrument encompasses reliability and validity analyses. Internal consistency reliability determines if there is satisfactory correlation between items within the same multi-item scale. Test-retest reliability assesses if there is good correlation between measurements of the same patient at 2 closely separated time points when major QOL discrepancy is not expected. Convergent validity tests for adequate correlation between conceptually related scales within the same instrument or a different validated instrument. Discriminant validity evaluates the ability to differentiate between patients of different clinical statuses. Responsiveness to change looks for significant change in score corresponding to patient’s improvement or deterioration in condition with time. Good convergence and discrimination are required for scaling success to support the hypothesized scale structure. These are the essential statistical analyses to validate QOL instruments.

**UTILIZATION OF HRQOL INSTRUMENTS**

HRQOL assessments have been conducted in HCC patents in different settings, and these are listed in Table 1.

***To describe symptomatology and HRQOL of HCC patients***

**Baseline QOL at HCC diagnosis:** HRQOL instruments were frequently used in HCC studies to assess baseline symptomatology and QOL of patients at presentation (Table 1). For instance, a case-control study compared baseline HRQOL of HCC patients at diagnosis with that of normal population[31]. HCC patients had significantly worse physical domain QOL but better environmental QOL of WHOQOL-BREF compared to healthy controls. Another case-control study reported bodily pain, role limitation-physical and physical component summary of SF-36 were significantly worse in HCC patients compared to matched cirrhotic control[32]. Similarly, another report found significantly worse physical, functional, emotional, social-family well-being and overall QOL of FACT-Hep in HCC patients when compared to general population; it also found significantly worse functional well-being and overall QOL in HCC patients when compared to controls with chronic liver disease[33].

**Observational studies with QOL assessment during treatment:** Many case series on HCC patients underdoing surgical resection, liver transplantation, local ablation, selective internal radiation therapy (SIRT) or transarterial chemoembolisation (TACE) for HCC also reported patients’ QOL.

HCC patients after curative intent treatment, for example partial hepatectomy, typically had transient deterioration in QOL followed by improvement of QOL. For long term survivors, their QOL could be comparable to that of control cirrhotic patients but worse than that of general population[34-37]. Patients with recurrent disease after curative treatment had deterioration in QOL[34].

In a prospective cohort study, 388 patients with solitary HCC of ≤3cm were treated with either surgical resection or percutaneous RFA, there was no difference in DFS or OS between the 2 groups. However, FACT-Hep total scores at 3, 6, 12, 24, 36 mo post treatment were significantly better in percutaneous RFA group compared to resection group[38].

A surgical series compared post operative QOL using SF-36 between liver transplantation (*n* = 95) and resection (*n* = 110) in HCC patients fulfilling Milan’s criteria. It reported no significant difference in all domains, physical component summary scale and mental component summary scale between these 2 cohorts. However it did not correlate with survival outcomes[39].

Patients received palliative locoregional therapies, *e.g.*, TACE, SIRT, stereotactic body radiation therapy (SBRT) commonly reported early deterioration of HRQOL, which could be attributable to treatment toxicity[40-43].

A case series reported HRQOL (SF-36) of HCC patients who received TACE[44]. Overall patients’ mental component summary scale improved at 4 mo after TACE. For patients received more than 2 cycles of TACE, their mental component summary scale improved after the initial 2 cycles of TACE, and their bodily pain score also improved. Another TACE series observed deterioration of physical health domain of WHOQOL-BREF that coincided with HCC progression[45]. A cohort study using FACT-Hep reported better functional well-being and overall QOL in HCC patients after treatment with SIRT when compared to TACE[46].

***As clinical trials endpoint***

HRQOL has been increasingly used as secondary endpoint in HCC clinical trials. Phase I/II trials put emphasis on treatment tolerability or toxicity, and thus QOL impact is a logical endpoint of interest. Quite a number of phase I/II HCC trials have QOL as secondary endpoints[47-57] (Table 1).

**QOL analysis in phase I/II clinical trials:** A phase I/II trial assessed the use of octreotide in 63 untreatable HCC patients[49]. Grade 3/4 toxicities were uncommon and responses were rare. QOL assessment using FACT-Hep was performed at baseline and every 1 mo afterwards. There was no significant change in reassessment QOL compared to baseline.

A combined analysis of 3 phase I/II trials of SBRT addressed the QOL of 98 HCC, 86 liver metastasis and 21 intrahepatic cholangiocarcinoma patients[42]. EORTC QLQ-C30 and FACT-Hep were used for QOL assessment, which was scheduled at baseline, 1, 3, 6 and 12 mo. Overall the QOL deteriorated at 1 month after SBRT, then recovered at 3 mo. Patients with liver metastasis had significantly better QOL at 1 and 6 mo than patients with primary liver cancer.

A randomized phase II trial evaluated TACE with microspheres *vs* TACE in 70 HCC patients[58]. G4 toxicities were rare in both arms. Global QOL domain of EORTC QLQ-C30 was used for QOL monitoring, which was measured at baseline and every 3 mo afterwards. There was no significant difference in QOL in both arms.

**QOL analysis in phase III clinical trials:** Although phase III trials focus on evaluation of treatment efficacy, there is an increasing trend for these phase III clinical trials to incorporate HRQOL as a study endpoint. Effective treatment could improve QOL, whereas treatment-related toxicity, disease progression with ineffective treatment could worsen QOL. Thus it is important to investigate whether a treatment could provide a net QOL benefit. Capturing HRQOL data in clinical trials could provide valuable information to guide clinicians in treatment decision. Commonly used tools included EORTC QLQ-C30, EORTC QLQ-HCC18, Spitzer QoL index, FACT-G, FACT-Hep, FHSI-8[12-14,59-65] (Table 1). Some trials defined *a priori* 1-2 scales of interest within an HRQOL instrument as study endpoint, *e.g.*, global QOL or physical functioning domain of EORTC QLQ-C30[60,61,65].

A phase III trial comparing first-line tamoxifen *vs* best supportive care alone in advanced HCC patients found no significant difference in OS in both arms. HRQOL, measured using Spitzer QoL index, decreased in both groups of patients with time[59].

A phase III trial compared first-line megestrol acetate *vs* placebo in advanced HCC patients[62]. There was no significant impact on OS with megestrol acetate. However, patients received megestrol acetate had significantly better scores in EORTC QLQ-C30 appetite loss, nausea/vomiting and emotional functioning scales compared to placebo. Such prospective randomized HRQOL data might provide rationale in using megestrol acetate for palliative symptom relief in advanced HCC patients.

The SHARP study and the phase III trial reported by Cheng *et al*[13] were pivotal trials demonstrating PFS and OS benefits of first-line sorafenib in advanced HCC patients compared to placebo[12]. Drug related serious adverse events were more frequent in sorafenib arm than placebo arm in both studies. Both trials employed deterioration in FHSI-8 score as one of the definitions of symptomatic progression. In both trials, median time to symptomatic progression was not significantly different between sorafenib and placebo arms.

The phase III BRISK-FL study randomized 1150 advanced HCC patients to first-line brivanib or sorafenib[63]. There was no significant difference in OS, time to tumor progression or response rate between the 2 arms. The overall incidence of serious adverse events was 56% for brivanib arm and 48% for sorafenib arm. The study used EORTC QLQ-C30 physical and role functioning domains as HRQOL endpoint. There was no significant difference in HRQOL at baseline between the 2 arms. The mean scores for physical and role functions declined at 12 wk in both brivanib and sorafenib patients, but the deterioration was significantly worse in brivanib arm. The objective of non-inferiority in OS was not met for brivanib. Should the onjective be met, the available QOL could potentially be a key in guiding clinicians on the use of a more tolerable agent (in this case sorafenib) which has less impairment in QOL.

From these first-line trials on tyrosine kinase inhibitors, it appear that the toxicity profile of brivanib was worse than sorafenib, while that of sorafenib was worse than placebo. The deterioration in QOL may be due to treatment-related toxicities, which can be offset by improvement in QOL due to disease control by a more effective treatment. This postulation could theoretically be explored in a meta-analysis of these studies, however, the usage of different HRQOL instruments across studies precluded such an attempt.

In the EVOLVE-1 trial, HCC patients who failed sorafenib were treated with everolimus or placebo[65]. Disease control rate was significantly better in the everolimus arm, but there was no significant difference in PFS or OS between the 2 arms. On the other hand, the time to definitive deterioration in EORTC QLQ-C30 physical functioning was significantly shorter in the everolimus arm. This might be related to the significantly increased incidence in grade 3/4 adverse events in the everolimus arm compared to the placebo arm. This study again exemplified the importance in inclusion of HRQOL assessment in clinical trial because the intervention itself could have negative effect on QOL.

The phase III RESORCE trial evaluated second-line regorafenib versus placebo in advanced HCC patients with prior sorafenib. Compared to placebo arm, patients randomized to regorafenib had significantly longer OS and PFS (using modified Response Evaluation Criteria in Solid Tumors for HCC), and reported more drug related adverse events. HRQOL was assessed using FACT-G, FACT-Hep, TOI, EQ-5D and EQ-VAS. The FACT-Hep total score and TOI were significantly lower in regorafenib arm than placebo arm, while FACT-G, EQ-5D and EQ-VAS were not significantly different[14]. Cost-effectiveness analysis of this expensive intervention is essential in parts of the world where medical resources are particularly limited, the use of EQ-5D will allow such analysis to be conducted.

***As prognostic tools for overall survival***

One interesting use of HRQOL data in HCC patients is prognostication for OS. Three studies showed that in advanced HCC patients, baseline HRQOL at diagnosis was prognostic for OS[66-68]. Our group reported the prognostic significance of EORTC QLQ-C30 in advanced HCC patients, where worse scores in appetite loss, physical function and role function domains were independent risk factors for shorter OS[66]. In another study using EORTC QLQ-C30, better baseline role function score was found to be a significant prognostic factor for longer OS in advanced HCC patients[68]. Baseline Spitzer QoL index was also reported to be prognostic of survival in 538 advanced HCC patients, where higher baseline Spitzer QoL index score was associated with longer OS[67]. However, a study recruiting HCC patients of all stages reported FACT-G was not prognostic of overall survival[69].

Our group subsequently evaluated the prognostic value of baseline EORTC QLQ-C30 and QLQ-HCC18 in a cohort of newly diagnosed HCC patients including all stages and found both were significant prognostic factors for OS irrespective of stage of disease[70]. Better scores in QLQ-C30 pain, QLQ-C30 physical functioning, QLQ-HCC18 pain, QLQ-HCC18 fatigue scales at diagnosis were significant independent prognostic factors for longer OS. In order to enhance the user-friendliness of these instruments, two summative scoring systems, the C30 index score and HCC18 index score, were derived. See Table 3 for the formulae.

Both of these scores were found to be highly significant factors for OS and their prognostic values resemble that of a staging system.

For C30 index score of 0-20, 21-40, 41-60, 61-100, the median OS were 16.4, 7.3, 3.1, 1.8 mo respectively (*P* < 0.0001). For HCC18 index score of 0-20, 21-40, 41-60, 61-100, the median OS were 16.4, 6.0, 2.8, 1.8 mo respectively (*P* < 0.0001).

Attempts have been made to enhance existing staging systems with HRQOL data[67,68]. Addition of EORTC QLQ-C30 data has been shown to improve the performance of the Cancer of the Liver Italian Program (CLIP)[71,72], the Barcelona Clinic Liver Cancer (BCLC) system[73], the Groupe d’Étude et de Traitement du Carcinome Hépatocellulaire (GRETCH) system[74]. Spitzer QoL index could improve the prognostic value of CLIP[67].

***Valuation of health care service***

Cost-effectiveness studies analyze the cost per outcome (effectiveness) of health care interventions, and compare this with reference to the country’s willingness to pay threshold. In cancer setting, this outcome is commonly QALY. HRQOL measurement allows valuation of HRQOL specific to the population. When this is combined with time, QALY could be calculated[75]. A popular instrument for this purpose is EQ-5D.

Certain treatments for HCC, such as liver transplantation and tyrosine kinase inhibitors, carry significant economic burden due to high utility and cost, particularly in areas with endemic hepatitis B viral infection. Cost-effectiveness analysis is therefore important to assist societal economic consideration by policy makers in health care service. A number of cost-effectiveness analyses in HCC have been carried out in this regard[76-81].

***Palliative care service benchmark***

HRQOL is an important benchmark for palliative care service and clinical trial[82]. Palliative care in cancer setting aims to improve QOL of cancer patients. It involves prevention, early identification and relief of sufferings (physical, psychological, social and spiritual) of cancer patients during the whole course of their illnesses. Therefore effective palliative care could be reflected in improvement in QOL.

Palliative care trials commonly recruit patients with a wide range of malignant diseases, including HCC. A prospective study conducted in Germany assessed the change in HRQOL using EORTC QLQ-C30 in cancer patients admitted to a hospital unit or palliative home care service where palliative treatment was given for symptoms relief[83]. Of all the patients who received palliative service for 7 d, 57% had a better rating in symptom domains and 42% had a better rating in functional domains when compared to their rating before receiving the service.

**DIFFICULTIES IN UTILIZATION OF HRQOL IN CLINICAL TRIAL AND PRACTICE**

***Prospective study design***

Although retrospective analysis of QOL can be conducted, HRQOL data have to be prospectively collected to be usable. Unless an institute has routine HRQOL assessment for all patients, a retrospective study is impossible to have HRQOL as a parameter.

***Choosing a suitable tool***

Choosing a suitable HRQOL instrument for a study could be challenging. Although the majority of the mentioned instruments were extensively validated, which instrument prevails over another is largely unknown. The aim of a study and the characteristics of individual HRQOL instruments should be considered. If the symptom aspect of HRQOL was of interest, one may favor an instrument housing more liver-cancer related symptoms, for example, EORTC QLQ-C30 plus QLQ-HCC18, or FACT-Hep. One should also take into account the instrument’s responsiveness to change with clinical condition in order to accurately capture significant HRQOL deterioration or improvement in subsequent reassessment time points. If follow up cost-effectiveness analysis of an intervention is anticipated, the study needs to include an instrument with QOL valuation ability, for example, EQ-5D.

***Missing data***

Missing data is common in HRQOL studies, and inadequate reporting and handling of missing data are also common[84]. Analysis of incomplete data could give biased results. Therefore missing data should be prevented, identified and handled appropriately.

Prevention of missing data should be planned before a study begins. As opposed to survival data that could be captured even when patients have succumbed, follow up QOL assessment relies mainly on active participation of patients. They need to have adequate physical and cognitive function and motivation to answer relevant questionnaires. This could be demanding to patients with deteriorated clinical status. This proves particularly challenging in clinical trial involving advanced HCC patients because their PFS generally is short and the clinical downhill course can be rapid. More frequent HRQOL reassessment may maximize the capture of HRQOL data before significant clinical deterioration occurs. Proxy (treating clinicians or patients’ care-giver) filled questionnaires could be a reasonable substitute[85] but still creates significant bias because HRQOL is a personal and subjective measurement. Computerized questionnaire during follow up visit could be programmed to forbid submission of incomplete questionnaire. Patients may forget to return reassessment questionnaires by mail if such system is utilized. Some studies employed reminder system to reduce this non-compliance.

When missing data occurred, it is essential to identify the mechanism of missing data and tackle it accordingly. There are 3 mechanisms of missing data: (1) missing completely at random (MCAR): MCAR is said to occur if the reason of missing data is unrelated to any variable of the study. For example, an on-site hand-held device for HRQOL assessment broke down for a certain period of time; (2) missing at random (MAR): If the reason of missing data was related to non-QOL data, MAR is present. For example, elderly patients are more prone to forget returning the reassessment questionnaire by mail than younger patients; (3) missing not at random (MNAR): MNAR is assumed when the reason of missing data is related to the QOL data. For example, severely ill patients with the worse QOL may feel too weak to complete reassessment questionnaires.

MCAR and MAR are categorized as ignorable missingness. Whereas MNAR is categorized as non-ignorable missingness, because the observed (available) QOL data are typically biased. Therefore it is important to investigate the mechanism of missing data in order to employ specific method of handling. Various statistical methods have been established to investigate the mechanism of missing data[86]. Nevertheless, confirmation of the underlying mechanism may not be possible. Once assumption of the mechanism is made, appropriate method to deal with missing data follows[87].

The following are the methods to handle missing data: (1) Complete case analysis: Patients with missing data are excluded from the analysis; (2) Single imputation: Single imputation replaces a missing value by a single value and analysis is carried out as if all data are observed. The replacement value could be the mean or mode of observed data, last observed value carried forward, baseline observed value carried forward, or predicted value from a regression equation based on information from observed data. Single imputation may have a higher risk of biasing the analysis because the uncertainty of imputed values was not addressed; (3) Multiple imputation: Multiple imputation generates multiple copies of the original dataset by replacing missing values using a specified regression model. Analysis is then performed for each dataset and the results are pooled into one estimate with standard error taking into account the uncertainty of the imputation process; (4) Statistical models: Mixed models and generalized estimating equations could be used to allow for missing data without imputation, making assumptions about their relationships with the observed data.

Option (1) will only be unbiased in case of MCAR or MAR. For MNAR, options (2-4) are more appropriate. Sensitivity analysis is then carried out. It involves separate analysis of every dataset generated by various imputation methods and comparison of the results. Sensitivity analysis reflects whether an analysis is robust (insignificant distortion of conclusion) after handling of missing data[88]. These are the key steps to minimize the detrimental effect of missing data on the results of QOL studies.

***Population related difference in HRQOL***

HRQOL changes significantly across different diseases, cultures and ethnicities. For example, in Chinese culture people take endurance as a merit, they often minimize the verbalization or expression of discomfort, thus symptoms scales might underestimate their symptomatology. Oriental culture tends not to discuss sex issue openly, therefore missing data rate in the sexual problem scale could be particularly high. Different languages and dialects could also affect patient’s interpretation of the intended questions. Therefore HRQOL instruments need validation in different countries, since HRQOL data from one country may not be applicable to another.

This is evident in a study that compared HRQOL between Asian and European HCC patients[89]. It reported significantly better scores in emotional functioning and insomnia (based on EORTC QLQ-C30) and sexual interest (based on EORTC QLQ-HCC18) in Asian when compared to European patients, after adjusting for demographic and clinical variables.

***Data interpretation***

Most HRQOL instruments consist of a collection of scores in various domains. How can one define a domain score being significantly good or bad? How can one define a clinically significant change in a domain score? Attempts have been made to evaluate minimally important differences in HRQOL measurements by comparing the scores among different patient groups stratified according to various clinical anchors, for example, stage of disease, performance status, *etc*[90-93]. This permits meaningful interpretation of HRQOL data. Studies sometimes employed these findings to define their HRQOL endpoints. However caution has to be exercised as these cutoffs or thresholds might be population- or disease-specific and might not be applicable to all.

***Data analysis***

Raw HRQOL ordinal data are commonly used as continuous variables in data analysis. Analysis is usually in the form of comparison of mean domain score between 2 patient groups or 2 time points within the same group. The situation is complicated by the fact that when all domain scores are included in a multivariate analysis model, the numerous raw HRQOL data could cause excessive multiple comparisons and instability of model[94,95].

Studies using limited number of domains within an HRQOL instrument may have avoided such problem, but may sacrifice potentially significant HRQOL variables.

Diouf *et al*[68] dichotomized all EORTC QLQ-C30 scale scores using 50 as an empirical cut-off for analysis. This may prevent overfitting and multi-collinearity and allows clinicians to understand HRQOL data in a simpler manner. As these cut-offs were supposed to be population-specific, another analysis was performed and reported the real cut-off for various scales[96].

Another way of HRQOL data analysis while avoiding multi-collinearity, yet without sacrificing any QOL data, is to use 1 score to represent all scales in the whole instrument. As discussed earlier, by transforming the EORTC QLQ-C30 into C30 index score, and EORTC QLQ-HCC18 into HCC18 index score for data analysis, our group has shown that these index scores were the most significant independent factors for OS among all the individual HRQOL variables, whether continuous or dichotomized[70].

Different studies used different HRQOL instruments. QOL data, unlike survival data or response assessment, are not unified to allow cross trial communication. Cross study comparison of HRQOL result is not usually possible. Performing meta-analysis on HRQOL studies is therefore difficult.

***Limitation for use in clinical practice***

Measurement of HRQOL in clinical practice is desirable. QOL changes over time in HCC patients when their diseases improve or progress, or when treatment complications arise. Deterioration in QOL reflects the need for palliative care intervention. However routine capturing of QOL data is difficult. Filling in the instruments, calculating all domain and total scores could be cumbersome in the clinical setting. Difficulty in interpretation of a collection of numerical scores also deters a clinician from welcoming it. Modern hand-held device might help patients to self-administer the questionnaires during waiting time, it can help generate all domain and total scores automatically, as well as support interpretation of individual score according to published local reference values.

**CONCLUSION**

Quality of life could be as important as survival in HCC patients because majority of them have advanced disease and limited survival. QOL measurement provides valuable information in clinical practice and research. Future research into utilization in clinical trials as well as routine clinical practice are warranted.

**REFERENCES**

1 **Chin PL**, Chu DZ, Clarke KG, Odom-Maryon T, Yen Y, Wagman LD. Ethnic differences in the behavior of hepatocellular carcinoma. *Cancer* 1999; **85**: 1931-1936 [PMID: 10223232 DOI: 10.1002/(SICI)1097-0142(19990501)85: 9<1931: : AID-CNCR8>3.0.CO; 2-O]

2 **Hsu C**, Shen YC, Cheng CC, Hu FC, Cheng AL. Geographic difference in survival outcome for advanced hepatocellular carcinoma: implications on future clinical trial design. *Contemp Clin Trials* 2010; **31**: 55-61 [PMID: 19737631 DOI: S1551-7144(09)00149-9]

3 **Zhang BH**, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. *J Cancer Res Clin Oncol* 2004; **130**: 417-422 [PMID: 15042359 DOI: 10.1007/s00432-004-0552-0]

4 **Regimbeau JM**, Kianmanesh R, Farges O, Dondero F, Sauvanet A, Belghiti J. Extent of liver resection influences the outcome in patients with cirrhosis and small hepatocellular carcinoma. *Surgery* 2002; **131**: 311-317 [PMID: 11894036]

5 **Marubashi S**, Gotoh K, Akita H, Takahashi H, Ito Y, Yano M, Ishikawa O, Sakon M. Anatomical versus non-anatomical resection for hepatocellular carcinoma. *Br J Surg* 2015; **102**: 776-784 [PMID: 25847111 DOI: 10.1002/bjs.9815]

6 **Sala M**, Llovet JM, Vilana R, Bianchi L, Solé M, Ayuso C, Brú C, Bruix J. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. *Hepatology* 2004; **40**: 1352-1360 [PMID: 15565564 DOI: 10.1002/hep.20465]

7 **Chen MS**, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ, Lin XJ, Lau WY. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. *Ann Surg* 2006; **243**: 321-328 [PMID: 16495695 DOI: 10.1097/01.sla.0000201480.65519.b8]

8 **Mazzaferro V**, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. *N Engl J Med* 1996; **334**: 693-699 [PMID: 8594428 DOI: 10.1056/nejm199603143341104]

9 **Llovet JM**, Real MI, Montaña X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Solà R, Rodés J, Bruix J. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. *Lancet* 2002; **359**: 1734-1739 [PMID: 12049862 DOI: 10.1016/S0140-6736(02)08649-X]

10 **Lo CM**, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST, Wong J. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. *Hepatology* 2002; **35**: 1164-1171 [PMID: 11981766 DOI: 10.1053/jhep.2002.33156]

11 **Sangro B**, Salem R, Kennedy A, Coldwell D, Wasan H. Radioembolization for hepatocellular carcinoma: a review of the evidence and treatment recommendations. *Am J Clin Oncol* 2011; **34**: 422-431 [PMID: 20622645 DOI: 10.1097/COC.0b013e3181df0a50]

12 **Llovet JM**, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J. Sorafenib in advanced hepatocellular carcinoma. *N Engl J Med* 2008; **359**: 378-390 [PMID: 18650514 DOI: 10.1056/NEJMoa0708857]

13 **Cheng AL**, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. *Lancet Oncol* 2009; **10**: 25-34 [PMID: 19095497 DOI: 10.1016/s1470-2045(08)70285-7]

14 **Bruix J**, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, Gerolami R, Masi G, Ross PJ, Song T, Bronowicki JP, Ollivier-Hourmand I, Kudo M, Cheng AL, Llovet JM, Finn RS, LeBerre MA, Baumhauer A, Meinhardt G, Han G. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet* 2017; **389**: 56-66 [PMID: 27932229 DOI: 10.1016/s0140-6736(16)32453-9]

15 **Aaronson NK**, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. *J Natl Cancer Inst* 1993; **85**: 365-376 [PMID: 8433390]

16 **Cella DF**, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. *J Clin Oncol* 1993; **11**: 570-579 [PMID: 8445433]

17 **Spitzer WO**, Dobson AJ, Hall J, Chesterman E, Levi J, Shepherd R, Battista RN, Catchlove BR. Measuring the quality of life of cancer patients: a concise QL-index for use by physicians. *J Chronic Dis* 1981; **34**: 585-597 [PMID: 7309824]

18 **Ware JE**, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. *Med Care* 1992; **30**: 473-483 [PMID: 1593914]

19 **Ware J**, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. *Med Care* 1996; **34**: 220-233 [PMID: 8628042]

20 [No authors listed]. The World Health Organization Quality of Life Assessment (WHOQOL): development and general psychometric properties. *Soc Sci Med* 1998; **46**: 1569-1585 [PMID: 9672396]

21 [No authors listed]. Development of the World Health Organization WHOQOL-BREF quality of life assessment. The WHOQOL Group. *Psychol Med* 1998; **28**: 551-558 [PMID: 9626712]

22 [**EuroQol Group**](https://www.ncbi.nlm.nih.gov/pubmed/?term=EuroQol%20Group%5BCorporate%20Author%5D)**.** EuroQol--a new facility for the measurement of health-related quality of life. *Health Policy* 1990; **16**: 199-208 [PMID: 10109801]

23 **Brooks R**. EuroQol: the current state of play. *Health Policy* 1996; **37**: 53-72 [PMID: 10158943]

24 **Blazeby JM**, Currie E, Zee BC, Chie WC, Poon RT, Garden OJ. Development of a questionnaire module to supplement the EORTC QLQ-C30 to assess quality of life in patients with hepatocellular carcinoma, the EORTC QLQ-HCC18. *Eur J Cancer* 2004; **40**: 2439-2444 [PMID: 15519517 DOI: 10.1016/j.ejca.2004.06.033]

25 **Heffernan N**, Cella D, Webster K, Odom L, Martone M, Passik S, Bookbinder M, Fong Y, Jarnagin W, Blumgart L. Measuring health-related quality of life in patients with hepatobiliary cancers: the functional assessment of cancer therapy-hepatobiliary questionnaire. *J Clin Oncol* 2002; **20**: 2229-2239 [PMID: 11980994]

26 **Yount S**, Cella D, Webster K, Heffernan N, Chang C, Odom L, van Gool R. Assessment of patient-reported clinical outcome in pancreatic and other hepatobiliary cancers: the FACT Hepatobiliary Symptom Index. *J Pain Symptom Manage* 2002; **24**: 32-44 [PMID: 12183093 DOI: 10.1016/S0885-3924(02)00422-0]

27 **Chie WC**, Blazeby JM, Hsiao CF, Chiu HC, Poon RT, Mikoshiba N, Al-Kadhimi G, Heaton N, Calara J, Collins P, Caddick K, Costantini A, Vilgrain V, Trinquart L, Chiang C. International cross-cultural field validation of an European Organization for Research and Treatment of Cancer questionnaire module for patients with primary liver cancer, the European Organization for Research and Treatment of Cancer quality-of-life questionnaire HCC18. *Hepatology* 2012; **55**: 1122-1129 [PMID: 22105642 DOI: 10.1002/hep.24798]

28 **Mikoshiba N**, Tateishi R, Tanaka M, Sakai T, Blazeby JM, Kokudo N, Koike K, Kazuma K. Validation of the Japanese version of the EORTC hepatocellular carcinoma-specific quality of life questionnaire module (QLQ-HCC18). *Health Qual Life Outcomes* 2012; **10**: 58 [PMID: 22651810 DOI: 10.1186/1477-7525-10-58]

29 **Ware JE**. SF-36 health survey update. *Spine (Phila Pa 1976)* 2000; **25**: 3130-3139 [PMID: 11124729]

30 **Pickard AS**, Wilke CT, Lin HW, Lloyd A. Health utilities using the EQ-5D in studies of cancer. *Pharmacoeconomics* 2007; **25**: 365-384 [PMID: 17488136]

31 **Lee LJ**, Chen CH, Yao G, Chung CW, Sheu JC, Lee PH, Tsai YJ, Wang JD. Quality of life in patients with hepatocellular carcinoma received surgical resection. *J Surg Oncol* 2007; **95**: 34-39 [PMID: 17192864 DOI: 10.1002/jso.20374]

32 **Bianchi G**, Loguercio C, Sgarbi D, Abbiati R, Brunetti N, De Simone T, Zoli M, Marchesini G. Reduced quality of life of patients with hepatocellular carcinoma. *Dig Liver Dis* 2003; **35**: 46-54 [PMID: 12725608]

33 **Steel JL**, Chopra K, Olek MC, Carr BI. Health-related quality of life: Hepatocellular carcinoma, chronic liver disease, and the general population. *Qual Life Res* 2007; **16**: 203-215 [PMID: 17119847 DOI: 10.1007/s11136-006-9111-2]

34 **Poon RT**, Fan ST, Yu WC, Lam BK, Chan FY, Wong J. A prospective longitudinal study of quality of life after resection of hepatocellular carcinoma. *Arch Surg* 2001; **136**: 693-699 [PMID: 11387012]

35 **Martin RC**, Eid S, Scoggins CR, McMasters KM. Health-related quality of life: return to baseline after major and minor liver resection. *Surgery* 2007; **142**: 676-684 [PMID: 17981187 DOI: 10.1016/j.surg.2007.04.026]

36 **Eid S**, Stromberg AJ, Ames S, Ellis S, McMasters KM, Martin RC. Assessment of symptom experience in patients undergoing hepatic resection or ablation. *Cancer* 2006; **107**: 2715-2722 [PMID: 17075874 DOI: 10.1002/cncr.22297]

37 **Kondo Y**, Yoshida H, Tateishi R, Shiina S, Mine N, Yamashiki N, Sato S, Kato N, Kanai F, Yanase M, Yoshida H, Akamatsu M, Teratani T, Kawabe T, Omata M. Health-related quality of life of chronic liver disease patients with and without hepatocellular carcinoma. *J Gastroenterol Hepatol* 2007; **22**: 197-203 [PMID: 17295871 DOI: 10.1111/j.1440-1746.2006.04456.x]

38 **Huang G**, Chen X, Lau WY, Shen F, Wang RY, Yuan SX, Geng WX, Zhou WP. Quality of life after surgical resection compared with radiofrequency ablation for small hepatocellular carcinomas. *Br J Surg* 2014; **101**: 1006-1015 [PMID: 24863168 DOI: 10.1002/bjs.9539]

39 **Lei JY**, Yan LN, Wang WT, Zhu JQ, Li DJ. Health-Related Quality of Life and Psychological Distress in Patients With Early-Stage Hepatocellular Carcinoma After Hepatic Resection or Transplantation. *Transplant Proc* 2016: 2107-2111 [PMID: 27569954 DOI: 10.1016/j.transproceed.2016.04.012]

40 **Brans B**, Lambert B, De Beule E, De Winter F, Van Belle S, Van Vlierberghe H, de Hemptinne B, Dierckx RA. Quality of life assessment in radionuclide therapy: a feasibility study of the EORTC QLQ-C30 questionnaire in palliative (131)I-lipiodol therapy. *Eur J Nucl Med Mol Imaging* 2002; **29**: 1374-1379 [PMID: 12271421 DOI: 10.1007/s00259-002-0918-y]

41 **Salem R**, Gilbertsen M, Butt Z, Memon K, Vouche M, Hickey R, Baker T, Abecassis MM, Atassi R, Riaz A, Cella D, Burns JL, Ganger D, Benson AB, Mulcahy MF, Kulik L, Lewandowski R. Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization. *Clin Gastroenterol Hepatol* 2013; **11**: 1358-1365.e1 [PMID: 23644386 DOI: 10.1016/j.cgh.2013.04.028]

42 **Klein J**, Dawson LA, Jiang H, Kim J, Dinniwell R, Brierley J, Wong R, Lockwood G, Ringash J. Prospective Longitudinal Assessment of Quality of Life for Liver Cancer Patients Treated With Stereotactic Body Radiation Therapy. *Int J Radiat Oncol Biol Phys* 2015; **93**: 16-25 [PMID: 26279020 DOI: 10.1016/j.ijrobp.2015.04.016]

43 **Ahmed S**, de Souza NN, Qiao W, Kasai M, Keem LJ, Shelat VG. Quality of Life in Hepatocellular Carcinoma Patients Treated with Transarterial Chemoembolization. *HPB Surg* 2016; **2016**: 6120143 [PMID: 27143815 DOI: 10.1155/2016/6120143]

44 **Wible BC**, Rilling WS, Drescher P, Hieb RA, Saeian K, Frangakis C, Chen Y, Eastwood D, Kim HS. Longitudinal quality of life assessment of patients with hepatocellular carcinoma after primary transarterial chemoembolization. *J Vasc Interv Radiol* 2010; **21**: 1024-1030 [PMID: 20621715 DOI: 10.1016/j.jvir.2010.03.005]

45 **Eltawil KM**, Berry R, Abdolell M, Molinari M. Quality of life and survival analysis of patients undergoing transarterial chemoembolization for primary hepatic malignancies: a prospective cohort study. *HPB (Oxford)* 2012; **14**: 341-350 [PMID: 22487072 DOI: 10.1111/j.1477-2574.2012.00455.x]

46 **Steel J**, Baum A, Carr B. Quality of life in patients diagnosed with primary hepatocellular carcinoma: hepatic arterial infusion of Cisplatin versus 90-Yttrium microspheres (Therasphere). *Psychooncology* 2004; **13**: 73-79 [PMID: 14872525 DOI: 10.1002/pon.725]

47 **Poon RT**, Yu WC, Fan ST, Wong J. Long-term oral branched chain amino acids in patients undergoing chemoembolization for hepatocellular carcinoma: a randomized trial. *Aliment Pharmacol Ther* 2004; **19**: 779-788 [PMID: 15043519 DOI: 10.1111/j.1365-2036.2004.01920.x]

48 **Kirchhoff TD**, Rudolph KL, Layer G, Chavan A, Greten TF, Rosenthal H, Kubicka S, Galanski M, Manns MP, Schild H, Gallkowski U. Chemoocclusion vs chemoperfusion for treatment of advanced hepatocellular carcinoma: a randomised trial. *Eur J Surg Oncol* 2006; **32**: 201-207 [PMID: 16373084 DOI: 10.1016/j.ejso.2005.11.003]

49 **Cebon J**, Findlay M, Hargreaves C, Stockler M, Thompson P, Boyer M, Roberts S, Poon A, Scott AM, Kalff V, Garas G, Dowling A, Crawford D, Ring J, Basser R, Strickland A, Macdonald G, Green M, Nowak A, Dickman B, Dhillon H, Gebski V. Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide. *Br J Cancer* 2006; **95**: 853-861 [PMID: 16953241 DOI: 10.1038/sj.bjc.6603325]

50 **Becker G**, Allgaier HP, Olschewski M, Zähringer A, Blum HE. Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study. *Hepatology* 2007; **45**: 9-15 [PMID: 17187405 DOI: 10.1002/hep.21468]

51 **Dimitroulopoulos D**, Xinopoulos D, Tsamakidis K, Zisimopoulos A, Andriotis E, Panagiotakos D, Fotopoulou A, Chrysohoou C, Bazinis A, Daskalopoulou D, Paraskevas E. Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: randomized placebo-controlled trial. *World J Gastroenterol* 2007; **13**: 3164-3170 [PMID: 17589893]

52 **Méndez Romero A**, Wunderink W, van Os RM, Nowak PJ, Heijmen BJ, Nuyttens JJ, Brandwijk RP, Verhoef C, Ijzermans JN, Levendag PC. Quality of life after stereotactic body radiation therapy for primary and metastatic liver tumors. *Int J Radiat Oncol Biol Phys* 2008; **70**: 1447-1452 [PMID: 17996394 DOI: 10.1016/j.ijrobp.2007.08.058]

53 **Soliman H**, Ringash J, Jiang H, Singh K, Kim J, Dinniwell R, Brade A, Wong R, Brierley J, Cummings B, Zimmermann C, Dawson LA. Phase II trial of palliative radiotherapy for hepatocellular carcinoma and liver metastases. *J Clin Oncol* 2013; **31**: 3980-3986 [PMID: 24062394 DOI: 10.1200/jco.2013.49.9202]

54 **Kolligs FT**, Bilbao JI, Jakobs T, Iñarrairaegui M, Nagel JM, Rodriguez M, Haug A, D'Avola D, op den Winkel M, Martinez-Cuesta A, Trumm C, Benito A, Tatsch K, Zech CJ, Hoffmann RT, Sangro B. Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma. *Liver Int* 2015; **35**: 1715-1721 [PMID: 25443863 DOI: 10.1111/liv.12750]

55 **Anota A**, Boulin M, Dabakuyo-Yonli S, Hillon P, Cercueil JP, Minello A, Jouve JL, Paoletti X, Bedenne L, Guiu B, Bonnetain F. An explorative study to assess the association between health-related quality of life and the recommended phase II dose in a phase I trial: idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma. *BMJ Open* 2016; **6**: e010696 [PMID: 27342239 DOI: 10.1136/bmjopen-2015-010696]

56 **Lv N**, Kong Y, Mu L, Pan T, Xie Q, Zhao M. Effect of perioperative parecoxib sodium on postoperative pain control for transcatheter arterial chemoembolization for inoperable hepatocellular carcinoma: a prospective randomized trial. *Eur Radiol* 2016; **26**: 3492-3499 [PMID: 26801163 DOI: 10.1007/s00330-016-4207-8]

57 **Koeberle D**, Dufour JF, Demeter G, Li Q, Ribi K, Samaras P, Saletti P, Roth AD, Horber D, Buehlmann M, Wagner AD, Montemurro M, Lakatos G, Feilchenfeldt J, Peck-Radosavljevic M, Rauch D, Tschanz B, Bodoky G. Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29). *Ann Oncol* 2016; **27**: 856-861 [PMID: 26884590 DOI: 10.1093/annonc/mdw054]

58 **Kirchhoff TD**, Rudolph KL, Layer G, Chavan A, Greten TF, Rosenthal H, Kubicka S, Galanski M, Manns MP, Schild H, Gallkowski U. Chemoocclusion vs chemoperfusion for treatment of advanced hepatocellular carcinoma: a randomised trial. *Eur J Surg Oncol* 2006; **32**: 201-207 [PMID: 16373084 DOI: 10.1016/j.ejso.2005.11.003]

59 **Barbare JC**, Bouché O, Bonnetain F, Raoul JL, Rougier P, Abergel A, Boige V, Denis B, Blanchi A, Pariente A, Milan C, Bedenne L. Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma. *J Clin Oncol* 2005; **23**: 4338-4346 [PMID: 15994145 DOI: 10.1200/jco.2005.05.470]

60 **Chow PK**, Tai BC, Tan CK, Machin D, Win KM, Johnson PJ, Soo KC. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial. *Hepatology* 2002; **36**: 1221-1226 [PMID: 12395333 DOI: 10.1053/jhep.2002.36824]

61 **Barbare JC**, Bouché O, Bonnetain F, Dahan L, Lombard-Bohas C, Faroux R, Raoul JL, Cattan S, Lemoine A, Blanc JF, Bronowicki JP, Zarski JP, Cazorla S, Gargot D, Thevenot T, Diaz E, Bastie A, Aparicio T, Bedenne L. Treatment of advanced hepatocellular carcinoma with long-acting octreotide: a phase III multicentre, randomised, double blind placebo-controlled study. *Eur J Cancer* 2009; **45**: 1788-1797 [PMID: 19303768 DOI: 10.1016/j.ejca.2009.02.018]

62 **Chow PK**, Machin D, Chen Y, Zhang X, Win KM, Hoang HH, Nguyen BD, Jin MY, Lobo R, Findlay M, Lim CH, Tan SB, Gandhi M, Soo KC. Randomised double-blind trial of megestrol acetate vs placebo in treatment-naive advanced hepatocellular carcinoma. *Br J Cancer* 2011; **105**: 945-952 [PMID: 21863030 DOI: 10.1038/bjc.2011.333]

63 **Johnson PJ**, Qin S, Park JW, Poon RT, Raoul JL, Philip PA, Hsu CH, Hu TH, Heo J, Xu J, Lu L, Chao Y, Boucher E, Han KH, Paik SW, Robles-Aviña J, Kudo M, Yan L, Sobhonslidsuk A, Komov D, Decaens T, Tak WY, Jeng LB, Liu D, Ezzeddine R, Walters I, Cheng AL. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. *J Clin Oncol* 2013; **31**: 3517-3524 [PMID: 23980084 DOI: 10.1200/jco.2012.48.4410]

64 **Meyer T**, Kirkwood A, Roughton M, Beare S, Tsochatzis E, Yu D, Davies N, Williams E, Pereira SP, Hochhauser D, Mayer A, Gillmore R, O'Beirne J, Patch D, Burroughs AK. A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma. *Br J Cancer* 2013; **108**: 1252-1259 [PMID: 23449352 DOI: 10.1038/bjc.2013.85]

65 **Zhu AX**, Kudo M, Assenat E, Cattan S, Kang YK, Lim HY, Poon RT, Blanc JF, Vogel A, Chen CL, Dorval E, Peck-Radosavljevic M, Santoro A, Daniele B, Furuse J, Jappe A, Perraud K, Anak O, Sellami DB, Chen LT. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. *JAMA* 2014; **312**: 57-67 [PMID: 25058218 DOI: 10.1001/jama.2014.7189]

66 **Yeo W**, Mo FK, Koh J, Chan AT, Leung T, Hui P, Chan L, Tang A, Lee JJ, Mok TS, Lai PB, Johnson PJ, Zee B. Quality of life is predictive of survival in patients with unresectable hepatocellular carcinoma. *Ann Oncol* 2006; **17**: 1083-1089 [PMID: 16600982 DOI: 10.1093/annonc/mdl065]

67 **Bonnetain F**, Paoletti X, Collette S, Doffoel M, Bouché O, Raoul JL, Rougier P, Masskouri F, Barbare JC, Bedenne L. Quality of life as a prognostic factor of overall survival in patients with advanced hepatocellular carcinoma: results from two French clinical trials. *Qual Life Res* 2008; **17**: 831-843 [PMID: 18618292 DOI: 10.1007/s11136-008-9365-y]

68 **Diouf M**, Filleron T, Barbare JC, Fin L, Picard C, Bouché O, Dahan L, Paoletti X, Bonnetain F. The added value of quality of life (QoL) for prognosis of overall survival in patients with palliative hepatocellular carcinoma. *J Hepatol* 2013; **58**: 509-521 [PMID: 23178978 DOI: 10.1016/j.jhep.2012.11.019]

69 **Fielding R**, Wong WS. Quality of life as a predictor of cancer survival among Chinese liver and lung cancer patients. *Eur J Cancer* 2007; **43**: 1723-1730 [PMID: 17588741 DOI: 10.1016/j.ejca.2007.05.002]

70 **Li L**, Mo FK, Chan SL, Hui EP, Tang NS, Koh J, Leung LK, Poon AN, Hui J, Chu CM, Lee KF, Ma BB, Lai PB, Chan AT, Yu SC, Yeo W. Prognostic values of EORTC QLQ-C30 and QLQ-HCC18 index-scores in patients with hepatocellular carcinoma - clinical application of health-related quality-of-life data. *BMC Cancer* 2017; **17**: 8 [PMID: 28052758 DOI: 10.1186/s12885-016-2995-5]

71 [No authors listed]. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. *Hepatology* 1998; **28**: 751-755 [PMID: 9731568 DOI: 10.1002/hep.510280322]

72 [No authors listed]. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) Investigators. *Hepatology* 2000; **31**: 840-845 [PMID: 10733537 DOI: 10.1053/he.2000.5628]

73 **Llovet JM**, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. *Semin Liver Dis* 1999; **19**: 329-338 [PMID: 10518312]

74 **Chevret S**, Trinchet JC, Mathieu D, Rached AA, Beaugrand M, Chastang C. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire. *J Hepatol* 1999; **31**: 133-141 [PMID: 10424293 DOI: 10.1016/S0168-8278(99)80173-1]

75 **Rabin R**, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. *Ann Med* 2001; **33**: 337-343 [PMID: 11491192]

76 **Cucchetti A**, Trevisani F, Cappelli A, Mosconi C, Renzulli M, Pinna AD, Golfieri R. Cost-effectiveness of doxorubicin-eluting beads versus conventional trans-arterial chemo-embolization for hepatocellular carcinoma. *Dig Liver Dis* 2016; **48**: 798-805 [PMID: 27263056 DOI: 10.1016/j.dld.2016.03.031]

77 **Leung HW**, Liu CF, Chan AL. Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma. *Radiat Oncol* 2016; **11**: 69 [PMID: 27193904 DOI: 10.1186/s13014-016-0644-4]

78 **Lim KC**, Wang VW, Siddiqui FJ, Shi L, Chan ES, Oh HC, Tan SB, Chow PK. Cost-effectiveness analysis of liver resection versus transplantation for early hepatocellular carcinoma within the Milan criteria. *Hepatology* 2015; **61**: 227-237 [PMID: 24638991 DOI: 10.1002/hep.27135]

79 **Spolverato G**, Vitale A, Ejaz A, Kim Y, Maithel SK, Cosgrove DP, Pawlik TM. The relative net health benefit of liver resection, ablation, and transplantation for early hepatocellular carcinoma. *World J Surg* 2015; **39**: 1474-1484 [PMID: 25665675 DOI: 10.1007/s00268-015-2987-7]

80 **Zhang P**, Yang Y, Wen F, He X, Tang R, Du Z, Zhou J, Zhang J, Li Q. Cost-effectiveness of sorafenib as a first-line treatment for advanced hepatocellular carcinoma. *Eur J Gastroenterol Hepatol* 2015; **27**: 853-859 [PMID: 25919775 DOI: 10.1097/meg.0000000000000373]

81 **Zhang P**, Wen F, Li Q. FOLFOX4 or sorafenib as the first-line treatments for advanced hepatocellular carcinoma: A cost-effectiveness analysis. *Dig Liver Dis* 2016; **48**: 1492-1497 [PMID: 27486048 DOI: 10.1016/j.dld.2016.07.007]

82 **Kaasa S**, Loge JH. Quality-of-life assessment in palliative care. *Lancet Oncol* 2002; **3**: 175-182 [PMID: 11902505]

83 **Jocham HR**, Dassen T, Widdershoven G, Halfens RJ. Quality-of-life assessment in a palliative care setting in Germany: an outcome evaluation. *Int J Palliat Nurs* 2009; **15**: 338-345 [PMID: 19648849 DOI: 10.12968/ijpn.2009.15.7.43424]

84 **Fielding S**, Ogbuagu A, Sivasubramaniam S, MacLennan G, Ramsay CR. Reporting and dealing with missing quality of life data in RCTs: has the picture changed in the last decade? *Qual Life Res* 2016; **25**: 2977-2983 [PMID: 27650288 DOI: 10.1007/s11136-016-1411-6]

85 **Steel JL**, Geller DA, Carr BI. Proxy ratings of health related quality of life in patients with hepatocellular carcinoma. *Qual Life Res* 2005; **14**: 1025-1033 [PMID: 16041898]

86 **Fielding S**, Fayers PM, Ramsay CR. Investigating the missing data mechanism in quality of life outcomes: a comparison of approaches. *Health Qual Life Outcomes* 2009; **7**: 57 [PMID: 19545408 DOI: 10.1186/1477-7525-7-57]

87 **Bell ML**, Fiero M, Horton NJ, Hsu CH. Handling missing data in RCTs; a review of the top medical journals. *BMC Med Res Methodol* 2014; **14**: 118 [PMID: 25407057 DOI: 10.1186/1471-2288-14-118]

88 **Thabane L**, Mbuagbaw L, Zhang S, Samaan Z, Marcucci M, Ye C, Thabane M, Giangregorio L, Dennis B, Kosa D, Borg Debono V, Dillenburg R, Fruci V, Bawor M, Lee J, Wells G, Goldsmith CH. A tutorial on sensitivity analyses in clinical trials: the what, why, when and how. *BMC Med Res Methodol* 2013; **13**: 92 [PMID: 23855337 DOI: 10.1186/1471-2288-13-92]

89 **Chie WC**, Blazeby JM, Hsiao CF, Chiu HC, Poon RT, Mikoshiba N, Al-Kadhim G, Heaton N, Calara J, Collins P, Caddick K, Costantini A, Vilgrain V. Differences in health-related quality of life between European and Asian patients with hepatocellular carcinoma. *Asia Pac J Clin Oncol* 2016 [PMID: 27038366 DOI: 10.1111/ajco.12464]

90 **King MT**. The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. *Qual Life Res* 1996; **5**: 555-567 [PMID: 8993101]

91 **Osoba D**, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. *J Clin Oncol* 1998; **16**: 139-144 [PMID: 9440735 DOI: 10.1200/jco.1998.16.1.139]

92 **Cella D**, Hahn EA, Dineen K. Meaningful change in cancer-specific quality of life scores: differences between improvement and worsening. *Qual Life Res* 2002; **11**: 207-221 [PMID: 12074259]

93 **Pickard AS**, Neary MP, Cella D. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. *Health Qual Life Outcomes* 2007; **5**: 70 [PMID: 18154669 DOI: 10.1186/1477-7525-5-70]

94 **Van Steen K**, Curran D, Kramer J, Molenberghs G, Van Vreckem A, Bottomley A, Sylvester R. Multicollinearity in prognostic factor analyses using the EORTC QLQ-C30: identification and impact on model selection. *Stat Med* 2002; **21**: 3865-3884 [PMID: 12483772 DOI: 10.1002/sim.1358]

95 **Gotay CC,** Kawamoto CT, Bottomley A, Efficace F. The prognostic significance of patient-reported outcomes in cancer clinical trials. *J Clin Oncol* 2008: 1355-1363

96 **Diouf M**, Bonnetain F, Barbare JC, Bouché O, Dahan L, Paoletti X, Filleron T. Optimal cut points for quality of life questionnaire-core 30 (QLQ-C30) scales: utility for clinical trials and updates of prognostic systems in advanced hepatocellular carcinoma. *Oncologist* 2015; **20**: 62-71 [PMID: 25542450 DOI: 10.1634/theoncologist.2014-0175]

97 **Steel JL**, Eton DT, Cella D, Olek MC, Carr BI. Clinically meaningful changes in health-related quality of life in patients diagnosed with hepatobiliary carcinoma. *Ann Oncol* 2006; **17**: 304-312 [PMID: 16357021 DOI: 10.1093/annonc/mdj072]

98 **Steel J**, Hess SA, Tunke L, Chopra K, Carr BI. Sexual functioning in patients with hepatocellular carcinoma. *Cancer* 2005; **104**: 2234-2243 [PMID: 16220558 DOI: 10.1002/cncr.21450]

99 **Wang YB**, Chen MH, Yan K, Yang W, Dai Y, Yin SS. Quality of life after radiofrequency ablation combined with transcatheter arterial chemoembolization for hepatocellular carcinoma: comparison with transcatheter arterial chemoembolization alone. *Qual Life Res* 2007; **16**: 389-397 [PMID: 17111232 DOI: 10.1007/s11136-006-9133-9]

100 **Sun V**, Ferrell B, Juarez G, Wagman LD, Yen Y, Chung V. Symptom concerns and quality of life in hepatobiliary cancers. *Oncol Nurs Forum* 2008; **35**: E45-E52 [PMID: 18467279 DOI: 10.1188/08.onf.e45-e52]

101 **Doffoël M**, Bonnetain F, Bouché O, Vetter D, Abergel A, Fratté S, Grangé JD, Stremsdoerfer N, Blanchi A, Bronowicki JP, Caroli-Bosc FX, Causse X, Masskouri F, Rougier P, Bedenne L. Multicentre randomised phase III trial comparing Tamoxifen alone or with Transarterial Lipiodol Chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Fédération Francophone de Cancérologie Digestive 9402). *Eur J Cancer* 2008; **44**: 528-538 [PMID: 18242076 DOI: 10.1016/j.ejca.2008.01.004]

102 **Dollinger MM**, Lautenschlaeger C, Lesske J, Tannapfel A, Wagner AD, Schoppmeyer K, Nehls O, Welker MW, Wiest R, Fleig WE. Thymostimulin versus placebo for palliative treatment of locally advanced or metastasised hepatocellular carcinoma: a phase III clinical trial. *BMC Cancer* 2010; **10**: 457 [PMID: 20735834 DOI: 10.1186/1471-2407-10-457]

103 **Shun SC**, Chen CH, Sheu JC, Liang JD, Yang JC, Lai YH. Quality of life and its associated factors in patients with hepatocellular carcinoma receiving one course of transarterial chemoembolization treatment: a longitudinal study. *Oncologist* 2012; **17**: 732-739 [PMID: 22511265 DOI: 10.1634/theoncologist.2011-0368]

104 **Qiao CX**, Zhai XF, Ling CQ, Lang QB, Dong HJ, Liu Q, Li MD. Health-related quality of life evaluated by tumor node metastasis staging system in patients with hepatocellular carcinoma. *World J Gastroenterol* 2012; **18**: 2689-2694 [PMID: 22690079 DOI: 10.3748/wjg.v18.i21.2689]

105 **Fan SY**, Eiser C, Ho MC, Lin CY. Health-related quality of life in patients with hepatocellular carcinoma: the mediation effects of illness perceptions and coping. *Psychooncology* 2013; **22**: 1353-1360 [PMID: 22847677 DOI: 10.1002/pon.3146]

106 **Brunocilla PR**, Brunello F, Carucci P, Gaia S, Rolle E, Cantamessa A, Castiglione A, Ciccone G, Rizzetto M. Sorafenib in hepatocellular carcinoma: prospective study on adverse events, quality of life, and related feasibility under daily conditions. *Med Oncol* 2013; **30**: 345 [PMID: 23263829 DOI: 10.1007/s12032-012-0345-2]

107 **Mise Y**, Satou S, Ishizawa T, Kaneko J, Aoki T, Hasegawa K, Sugawara Y, Makuuchi M, Kokudo N. Impact of surgery on quality of life in patients with hepatocellular carcinoma. *World J Surg* 2014; **38**: 958-967 [PMID: 24305919 DOI: 10.1007/s00268-013-2342-9]

108 **Palmieri VO**, Santovito D, Margari F, Lozupone M, Minerva F, Di Gennaro C, Todarello O, Palasciano G. Psychopathological profile and health-related quality of life (HRQOL) in patients with hepatocellular carcinoma (HCC) and cirrhosis. *Clin Exp Med* 2015; **15**: 65-72 [PMID: 24323278 DOI: 10.1007/s10238-013-0267-0]

109 **Chie WC**, Yu F, Li M, Baccaglini L, Blazeby JM, Hsiao CF, Chiu HC, Poon RT, Mikoshiba N, Al-Kadhimi G, Heaton N, Calara J, Collins P, Caddick K, Costantini A, Vilgrain V, Chiang C. Quality of life changes in patients undergoing treatment for hepatocellular carcinoma. *Qual Life Res* 2015; **24**: 2499-2506 [PMID: 25943170 DOI: 10.1007/s11136-015-0985-8]

110 **Heits N**, Meer G, Bernsmeier A, Guenther R, Malchow B, Kuechler T, Becker T, Braun F. Mode of allocation and social demographic factors correlate with impaired quality of life after liver transplantation. *Health Qual Life Outcomes* 2015; **13**: 162 [PMID: 26420554 DOI: 10.1186/s12955-015-0360-z]

111 **Xie ZR**, Luo YL, Xiao FM, Liu Q, Ma Y. Health-related quality of life of patients with intermediate hepatocellular carcinoma after liver resection or transcatheter arterial chemoembolization. *Asian Pac J Cancer Prev* 2015; **16**: 4451-4456 [PMID: 26028113]

112 **Xing M**, Webber G, Prajapati HJ, Chen Z, El-Rayes B, Spivey JR, Pillai AA, Kim HS. Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study. *J Gastroenterol Hepatol* 2015; **30**: 1167-1174 [PMID: 25675849 DOI: 10.1111/jgh.12920]

113 **Yang B**, You X, Yuan ML, Qin TQ, Duan LJ, He J, Fei ZJ, Zhou X, Zan RY, Liao ZY. Transarterial Ethanol Ablation Combined with Transarterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. *Hepat Mon* 2016; **16**: e37584 [PMID: 27799963 DOI: 10.5812/hepatmon.37584]

114 **Shomura M**, Kagawa T, Okabe H, Shiraishi K, Hirose S, Arase Y, Tsuruya K, Takahira S, Mine T. Longitudinal alterations in health-related quality of life and its impact on the clinical course of patients with advanced hepatocellular carcinoma receiving sorafenib treatment. *BMC Cancer* 2016; **16**: 878 [PMID: 27835949 DOI: 10.1186/s12885-016-2908-7]

**P- Reviewer:** Kamiyama T, Ratnasari N, Richter B, Sazci A

**S- Editor:** Song XX **L- Editor:** **E- Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** China

**Peer-review report classification**

Grade A (Excellent): A

Grade B (Very good): B, B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**Table 1 Clinical studies in hepatocellular carcinoma that involved health related quality of life assessment**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Year** | **Study type** | **n** | **HCC status** | **Intervention(s)** | **HRQOL instruments used** | **HRQOL assessment time point(s)** | **Remarks** |
| Poon *et al*[34] | 2001 | Cohort | 76 | Resectable and unresectable | Resection (66) *vs* TACE (10) | FACT-G | Baseline, 3, 6, 7, 12, 18 and 24 mo | Observational study with QOL assessment during treatment |
| Brans *et al*[40] | 2002 | Cohort | 26 | Unresectable | SIRT (14) *vs* TACE (14) | EORTC QLQ-C30 | Baseline, 1 and 3 mo | Observational study with QOL assessment during treatment |
| Bianchi *et al*[32] | 2002 | Case-control | 101 | Any stage | NA | SF-36 | Baseline | To describe symptomatology and/or HRQOL of HCC patients -HRQOL of HCC patients compared to 202 matched cirrhotic patients |
| Chow *et al*[60] | 2002 | Phase III trial | 329 | Unresectable | Tamoxifen 120 mg/d (121) *vs* tamoxifen 60 mg/d (76) *vs* placebo (132) | global QOL domain of EORTC QLQ-C30 | Baseline, then every 1 mo | Phase III trial with HRQOL endpoint |
| Steel *et al*[46] | 2004 | Cohort | 28 | Allocated to SIRT or TACE | SIRT (14) *vs* TACE (14) | FACT-Hep, HepCS, TOI, FHSI8 | Baseline, 3, 6 and 12 mo | Observational study with QOL assessment during treatment.  Included in [97] |
| Poon *et al*[47] | 2004 | Randomized phase II trial | 88 | Allocated to TACE | Branched chained amino acid *vs* control | FACT-G | Baseline, 3, 6, 9 and 12 months | Phase II trial with HRQOL endpoint |
| Steel *et al*[85] | 2005 | Cohort | 82 | Any stage | Various treatments | FACT-Hep, HepCS, TOI, FHSI8 | Baseline, 3 and 6 mo | To describe symptomatology and/or HRQOL of HCC patients -Compared HRQOL between patients and proxy-raters.  Included in [97] |
| Steel *et al*[98] | 2005 | Case-control | 21 | TNM stage III or IV | NA | FACT-Hep, Sexual History Questionnaire | Baseline | To describe symptomatology and/or HRQOL of HCC patients - Included 23 patients with chronic liver disease |
| Barbare *et al*[59] | 2005 | Phase III trial | 420 | Not eligible for resection or local treatment | Tamoxifen (210) *vs* control (210) | Spitzer QoL index | Baseline, then every 3 mo | Phase III trial with HRQOL endpoint |
| Kirchhoff *et al*[48] | 2005 | Randomized phase II trial | 70 | Eligible for TACE | TACE with microspheres (35) *vs* TACE (35) | Global QOL of EORTC QLQ-C30 | Baseline, then every 6 mo | Phase II trial with HRQOL endpoint |
| Steel *et al*[97] | 2006 | Combined analysis of 3 studies | 157 | Mixed patient populations from 3 studies | Various treatments | FACT-Hep, HepCS, TOI, FHSI8 | Baseline, 3 and 6 mo | Observational study with QOL assessment during treatment - evaluates minimally important difference in HRQOL |
| Eid *et al*[36] | 2006 | Cohort | 7 | Allocated to hepatic ablation or resection | Hepatic ablation (3) *vs* resection (4) | EORTC QLQ-C30, FACT-Hep, FHSI8, Profile of Mood States (POMS) | Baseline, postoperative visit, 1.5, 3 and 6 mo | Observational study with QOL assessment during treatment. Study included other liver tumor types (33 patients) |
| Yeo *et al*[66] | 2006 | Combined analysis of 2 phase III trials | 233 | Unresectable or metastatic | Chemotherapy, hormonal therapy | EORTC QLQ-C30 | Baseline | As prognostic tools for overall survival - baseline HRQOL was prognostic of overall survival in advanced HCC |
| Wang *et al*[99] | 2006 | Cohort | 83 | Non-metastatic, 3 nodules or less | TACE + RFA (43) *vs* TACE (40) | FACT-G | Baseline, 3 mo | Observational study with QOL assessment during treatment |
| Cebon *et al*[49] | 2006 | Phase I/II trial | 63 | Not eligible for standard therapies | Octreotide long acting release | FACT-Hep, patient disease and treatment assessment form (Pt DATA form), patient benefit form | Baseline, then every 1 mo | Phase I/II trial with HRQOL endpoint |
| Llovet *et al*[12] | 2006 | Phase III trial | 602 | Not eligible for local treatment or had disease progression after surgery or local treatment | Sorafenib (299) *vs* placebo (303) | FHSI-8 | Baseline then every 3 wk | Phase III trial with HRQOL endpoint |
| Lee[31] | 2007 | Case control | 161 | Any stage | Surgical, TACE, percutaneous ethanol injection, supportive care | EORTC QLQ-C30, WHOQOL-BREF | Cross sectional one-time assessment | To describe symptomatology and/or HRQOL of HCC patients - compared with national matched healthy controls |
| Kondo *et al*[37] | 2007 | Case-control | 97 | Non-metastatic, 3 nodules or less | Percutaneous ablation | SF-36 | Baseline | To describe symptomatology and/or HRQOL of HCC patients - HRQOL compared to 97 matched chronic liver disease controls, and normal population values |
| Steel *et al*[33] | 2007 | Case-control | 83 | Any stage | NA | FACT-Hep | Baseline | To describe symptomatology and/or HRQOL of HCC patients - HRQOL compared to 51 matched chronic liver disease controls, and 138 controls from general population |
| Martin *et al*[35] | 2007 | Cohort | 4 | Resectable | Resection | EORTC QLQ-C30, FACT-Hep, FHSI-8 | Baseline, discharge, postoperative visit, 1.5, 3, 6 and 12 mo | Observational study with QOL assessment during treatment.  Included 28 patients with other liver tumors |
| Becker *et al*[50] | 2007 | Randomized phase II trial | 120 | Not eligible for resection or local treatment | Octreotide (61) *vs* placebo (59) | EORTC QLQ-C30 | Baseline, 1, 3 months, then every 3 mo | Phase II trial with HRQOL endpoint |
| Dimitroulopoulos *et al*[51] | 2007 | Randomized phase II trial | 127 | Advanced stage. Somatostatin receptor overexpression for randomisation | Octreotide (31) *vs* placebo (30) observation (66) | EORTC QLQ-C30 | Baseline then every 1 mo | Phase II trial with HRQOL endpoint |
| Sun *et al*[100] | 2008 | Cohort | 22 | Mainly advanced disease | Various treatments | FACT-Hep, Functional assessment of chronic illness therapy spirituality subscale (FACIT-Sp-12 ) | Baseline, 1, 2 and 3 mo | Observational study with QOL assessment during treatment.  Included 23 patients with pancreatic cancer |
| Mendez Romero  *et al*[52] | 2008 | Phase I/II trial | 9 | Not eligible for other local treatments | SBRT | EORTC QLQ-C30  EQ-5D VAS | Baseline, 1, 3 and 6 mo | Observational study with QOL assessment during treatment.  Included 19 patients with liver metastases. Phase I/II trial with HRQOL endpoint |
| Bonnetain *et al*[67] | 2008 | Combined analysis of 2 phase III trials[59, 101] | 538 | Not eligible for resection, transplantation or percutaneous ablation | Tamoxifen *vs* supportive care; TACE + tamoxifen *vs* tamoxifen | Spitzer QoL index | Baseline | As prognostic tools for overall survival - baseline HRQOL was prognostic of overall survival in advanced HCC |
| Doffoel *et al*[101] | 2008 | Phase III trial | 138 | Eligible for TACE | TACE + tamoxifen (70) *vs* tamoxifen (68) | Spitzer QoL index | Baseline, then every 2 mo during treatment, every 3 mo after treatment | Phase III trial with HRQOL endpoint |
| Barbare *et al*[61] | 2009 | Phase III trial | 272 | Not eligible for curative treatment | Octreotide (135) *vs* placebo (137) | EORTC QLQ-C30 | Baseline, then every 1 mo during treatment, every 3 mo after treatment | Phase III trial with HRQOL endpoint |
| Cheng *et al*[13] | 2009 | Phase III trial | 271 | Unresectable or metastatic, no prior systemic therapy | Sorafenib (150) *vs* placebo (76) | FHSI-8. Physical well being domain of FACT-Hep | Baseline then every 3 wk | Phase III trial with HRQOL endpoint |
| Wible *et al*[44] | 2010 | Cohort | 73 | Allocated to TACE | TACE | SF-36 | Baseline, 4, 8 and 12 mo | Observational study with QOL assessment during treatment |
| Dollinger *et al*[102] | 2010 | Phase III trial | 135 | Locally advanced or metastatic | Thymostimulin (67) *vs* placebo (68) | FACT=Hep | Baseline then every 3 mo | Phase III trial with HRQOL endpoint |
| Chow *et al*[62] | 2011 | Phase III trial | 204 | Advanced disease, not eligible for standard therapies | Megestrol acetate (195) *vs* placebo (69) | EORTC QLQ-C30 | Baseline, then every 1 mo during treatment, then every 3 mo after treatment completed | Phase III trial with HRQOL endpoint |
| Shun *et al*[103] | 2012 | Cohort | 89 | Allocated to TACE | TACE | SF-12, Symptom Distress Scale, Hospital Anxiety and Depression Scale (HADS) | 3 d before discharge, 1 and 2 mo | Observational study with QOL assessment during treatment |
| Qiao *et al*[104] | 2012 | Observational | 140 | Any stage | NANANAdadsdfsaNA | FACT-epHHep | Baseline | To describe symptomatology and/or HRQOL of HCC patients - HRQOL worsens with advancing stage |
| Eltawil *et al*[45] | 2012 | Cohort | 48 | Allocated to TACE | TACE | WHOQOL-BREF | Baseline then every 3-4 mo | Observational study with QOL assessment during treatment |
| Fan *et al*[105] | 2012 | Cross sectional | 286 | Any stage |  | EORTC QLQ-C30, EORTC QLQ-HCC18 | Baseline | To describe symptomatology and/or HRQOL of HCC patients - HRQOL compared with population norms. Correlation between HRQOL and coping and illness perception. |
| Diouf *et al*[68] | 2013 | Reanalysis of a phase III trial[61] | 215 | Not eligible for curative treatment, baseline HRQOL data available | Octreotide *vs* placebo | EORTC QLQ-C30 | Baseline | As prognostic tools for overall survival - baseline HRQOL was prognostic of overall survival in advanced HCC. HRQOL data may improve existing staging systems. |
| Soliman *et al*[53] | 2013 | Phase II trial | 21 | Not eligible for or refractory to standard therapies, symptomatic | Liver radiotherapy | EORTC QLQ-C30, FACT-Hep, HepCS, TOI, FACT-G | Baseline, 1, 3 and 6 mo | Phase II trial with HRQOL endpoint. Included 20 patients with liver metastasis. |
| Salem *et al*[41] | 2013 | Cohort | 56 | Allocated to SIRT or TACE | SIRT (29), TACE (27) | FACT-Hep | Baseline, 2 and 4 wk | Observational study with QOL assessment during treatment |
| Brunocilla *et al*[106] | 2013 | Cohort | 36 | Allocated to sorafenib | Sorafenib | FACT-Hep, FHSI-8, FACT-G | Baseline, 1 wk, 1 and 2 mo | Observational study with QOL assessment during treatment |
| Johnson *et al*[63] | 2013 | Phase III trial | 1150 | Not eligible for resection or local treatment, no prior systemic treatment | Brivanib (577) *vs* sorafenib (578) | Physical function and role function of EORTC QLQ-C30 | Baseline then every 6 wk | Phase III trial with HRQOL endpoint |
| Meyer *et al*[64] | 2013 | Phase II/III trial | 86 | Unresectable, non-metastatic | TACE *vs* TAE | EORTC QLQ-C30, EORTC QLQ-HCC18 | Baseline, 1.5, 3 and 6 mo | Phase II trial with HRQOL endpoint |
| Mise *et al*[107] | 2014 | Cohort | 69 | Allocated to resection | Resection | SF-36 | Baseline then every 3 mo | Observational study with QOL assessment during treatment |
| Huang *et al*[38] | 2014 | Cohort | 388 | Solitary HCC ≤ 3 cm | Resection, radiofrequency ablation | FACT-Hep, HepCS, TOI, FACT-G | Baseline, 3, 6, 12, 24 and 36 mo | Observational study with QOL assessment during treatment |
| Zhu *et al*[65] | 2014 | Phase III trial | 564 | Progressive disease during or after sorafenib | Everolimus (362) *vs* placebo (184) | Global QOL and physical function of EORTC QLQ-C30 | Baseline, then multiple reassessments | Phase III trial with HRQOL endpoint |
| Palmieri *et al*[108] | 2015 | Case control | 24 | Any stage | NA | SF-36 | Baseline | To describe symptomatology and/or HRQOL of HCC patients - evaluates relationship between psychological profile and HRQOL in HCC. Included 22 cirrhotic patients without HCC, 20 control subjects. |
| Chie *et al*[109] | 2015 | Cohort | 171 | Allocated to respective treatments | Surgery (53), ablation (53), TACE (65) | EORTC QLQ-C30, EORTC QLQ-HCC18 | Baseline, then 4-6 wk for post-ablation/post-TACE, 12-15 wk post-operation | Observational study with QOL assessment during treatment |
| Heits *et al*[110] | 2015 | Cross sectional | 173 | Allocated to liver transplanation | liver transplantation | EORTC QLQ-C30 | At one variable time point post-transplantion | To describe symptomatology and/or HRQOL of HCC patients |
| Xie *et al*[111] | 2015 | Cohort | 102 | Allocated to resection or TACE | resection (58), TACE (44) | SF-36 | Baseline, 1, 3, 6, 12 and 24 mo | Observational study with QOL assessment during treatment |
| Xing *et al*[112] | 2015 | Cohort | 118 | Allocated to TACE | TACE with doxorubicin eluted beads | SF-36 | Baseline, 1-3, 6 and 12 mo | Observational study with QOL assessment during treatment |
| Kolligs *et al*[54] | 2015 | Randomized phase II trial | 28 | Allocated to SIRT or TACE | SIRT (13), TACE (15) | FACT-Hep | Baseline, then every 6 wk | Phase II trial with HRQOL endpoint |
| Klein *et al*[42] | 2015 | Combined analysis of prior phase I/II trials | 98 | Allocated to SBRT | SBRT | EORTC QL-C30, FACT-Hep | Baseline, 1, 3, 6 and 12 mo | Phase I/II trial with HRQOL endpoint |
| Kensinger *et al*[48] | 2016 | Case-control | 139 | Allocated to priority liver transplantation | Liver transplantation | SF-36 | Baseline, post transplantation | Observational study with QOL assessment during treatment -  included 362 subjects without HCC |
| Lei *et al*[39] | 2016 | Cohort | 205 | Allocated to resection or transplantation | Liver transplantation (110), resection (95) | SF-36 | Baseline, then every 1-2 mo for the first 6 months, then every 2-3 mo for the next 6 mo, then every 6 mo | Observational study with QOL assessment during treatment |
| Yang *et al*[113] | 2016 | Cohort | 17 | Portal vein thrombosis | TACE and transarterial ethanol ablation | EORTC QLQ-C30 | Baseline then every 1 mo | Observational study with QOL assessment during treatment |
| Anota *et al*[55] | 2016 | Phase I trial | 21 | Not eligible for curative treatment | TACE with idaurubicin eluted beads | EORTC QLQ-C30 | Baseline, 15, 30 and 60 d | Phase I trial with HRQOL endpoint |
| Chie *et al*[89] | 2016 | Case-control | 227 | Any stage | Various treatments | EORTC QLQ-C30, EORTC QLQ-HCC18 | Baseline, post-treatment | Observational study with QOL assessment during treatment - Compared HRQOL between Asian and European HCC patients |
| Lv *et al*[56] | 2016 | Randomized phase II trial | 120 | Allocated to TACE | COX2 inhibitor (60) *vs* placebo (60) | Locally developed questionnaire | Baseline, 24 and 48 h | Phase II trial with HRQOL endpoint |
| Koeberle *et al*[57] | 2016 | Randomized phase II trial | 106 | Unresectable or metastatic | Sorafenib + everolimus (60) *vs* sorafenib (46) | FACT-HepCS, EQ-VAS | Baseline, then every 2 wk until week 12 | Phase II trial with HRQOL endpoint |
| Shomura *et al*[114] | 2016 | Cohort | 54 | TNM stage IV | Sorafenib | SF-36 | Baseline, then every 3 mo | Observational study with QOL assessment during treatment |
| Bruix *et al*[14] | 2016 | Phase III trial | 573 | Progressive disease during sorafenib | Regorafenib (379) *vs* placebo (193) | FACT-Hep, TOI, FACT-G, EQ-5D, EQ-VAS | Baseline, then multiple reassessments | Phase III trial with HRQOL endpoint |
| Li *et al*[70] | 2017 | Cohort | 472 | Any stage | Various treatments | EORTC QLQ-C30, EORTC QLQ-HCC18, C30 index score, HCC18 index score | Baseline | As prognostic tools for overall survival - baseline HRQOL was prognostic of overall survival in advanced HCC. QOL derived scoring system resembles a staging system |

EORTC: European Organisation for Research and Treatment of Cancer; EQ-5D: EuroQoL-5D; FACT-G: Functional Assessment of Cancer Therapy – General; FACT-Hep: Functional Assessment of Cancer Therapy – Hepatobiliary; FHSI-8: Functional Assessment of Cancer Therapy - Hepatobiliary Symptom Index; HCC: Hepatocellular carcinoma; HepCS: Hepatobiliary cancer subscale; HRQOL: Health related quality of life; n: Sample size; NA: Not applicable; RFA: Radiofrequency ablation; SBRT: Stereotactic body radiation therapy; SF-12: Short Form 12; SF-36: Short Form 36; SIRT: Selective internal radiation therapy; Spitzer QoL Index: Spitzer Quality of Life Index; TACE: Transarterial chemoembolization; TOI: Trial Outcome Index; VAS: Visual analogue scale; WHOQOL-BREF: World Health Organization Quality of Life Assessment abbreviated version.

**Table 2 Health related quality of life instruments commonly used in hepatocellular carcinoma studies**

|  |  |
| --- | --- |
| **General instruments** | |
| **European Organization for Research and Treatment of Cancer QLQ-C30** | EORTC QLQ-C30 is a general cancer instrument containing multiple items, measured in multiple-point Likert scales, that reflect the multidimensionality of HRQOL construct [15]. It includes five functional domains (physical, role, cognitive, emotional and social), three symptom domains (fatigue, pain, nausea/vomiting), and a global health and QOL domain. Six single items assess common symptoms in cancer patients (dyspnea, appetite loss, sleep disturbance, constipation and diarrhea) and financial problem. All scales and domains are transformed to scores ranging from 0 to 100. A lower score for a functional or global QOL scale reflects a relatively poorer functioning level or global QOL, a higher score for a symptom/problem scale reflects a more disturbing symptom/problem |
| **Functional Assessment of Cancer Therapy - General** | The FACT-G questionnaire is a commonly used tool for HRQOL assessment in general cancer patients[16]. It consists of 27 items for assessment of symptoms and four domains of HRQOL: (1) physical well being (PWB) containing seven items with a subscale score ranging from 0 to 28 points; (2) socio-family well being (SFWB) containing seven items with a subscale score of 0–28 points; (3) emotional well being (EWB) containing six items with a subscale score of 0–24 points; and (4) functional well being (FWB) containing seven items with a subscale score of 0–28 points. Patients were asked to score each item according to how true each statement was to them during the past week on a 5-point ordinal scale, from 0 indicating “not at all” to 4 indicating “very much”. The FACT-G total score is the summation of the four subscales (PWB, FWB, SFWB and EWB) scores and can range from 0 to 108. Higher scores reflect better HRQOL |
| **Spitzer Quality of Life Index (Spitzer QoL index)** | Spitzer QoL index is a general cancer HRQOL measurement[17]. A score of 0 (worst QOL) to 10 (best QoL) was calculated after the patient answered five items of the questionnaire in the areas of activity, daily life, health perceptions, social support and behavior. Each item is rated on a 3-point Likert scale |
| **Short Form 36** | SF-36 is a general disease questionnaire to measure the following 8 domains of health: general health, bodily pain, social functioning, role-physical, physical functioning, vitality, role-emotional and mental health[18]. The raw scores of each subscale are converted to scores that range from 0 to 100, with higher scores indicating higher levels of functioning or well being. Scores representing overall physical functioning and mental functioning were calculated from the subscales and are grouped as the physical component summary scale and mental component summary scale |
| **Short Form 12** | SF-12 is a shortened version of SF-36. It contains a 12-item generic measure of health status developed from SF-36[19]. It also yields scores for eight domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. It likewise provides overall summaries of the physical and mental components |
| **World Health Organization Quality of Life Assessment 100** | The WHOQOL-100 questionnaire comprises of 100 items grouped into 25 facets[20]. One of the facets measures overall quality of life/health. The remaining 24 facets are organized in 6 domains: (1) physical health, (2) psychological health, (3) level of independence, (4) social relationships, (5) environment and (6) spirituality/religion/ personal beliefs. Each facet includes four items, rated on a 5-point Likert scale, with higher scores indicating more positive evaluations. Domain and facet raw scores can also be transformed onto a 0 to 100 scale. Higher scores denote higher HRQOL. |
| **World Health Organization Quality of Life Assessment abbreviated version** | The original 6-domain structure of WHOQOL-100 was subsequently reduced into 4 comprehensive domains by the WHOQOL Group, comprising: (1) physical health (merging the level of independence domain), (2) psychological health (merging the spirituality/religion/personal beliefs domain), (3) social relationships and (4) environment[21]. It contains a total of 26 questions. Attributes incorporated within the physical health domain of the WHOQOL-BREF include: activities of daily living, dependence on medicines or medical aids, energy and fatigue, mobility, pain and discomfort, sleep and rest and work capacity. Attributes incorporated within the psychological health domain are: body image and appearance, negative and positive feelings, self-esteem, spirituality, religion and personal beliefs, thinking, learning, memory and concentration. Measurements of social health domain include personal relationships, social support and sexual activity. Features incorporated in the environmental health domain are: financial resources, freedom, physical safety and security, health and social care, home environment, opportunities for acquiring the new information and skills, participation in and opportunities for recreation, physical environment and transportation. Higher scores denote higher HRQOL |
| **EuroQoL-5D** | EQ-5D is a general disease instrument for describing and valuing HRQOL developed by the EuroQoL Group[22,23]. The questionnaire consists of 2 sections: the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS).  The descriptive system contains one question in each of the 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). In the 3-point Likert version (EQ-5D-3L), each question has three levels of response: no problems, some problems or extreme problems. A specific value (weight) is attached to each response of each question according to that country’s specific value sets. Studies have been conducted to elicit preferences from general population samples to derive these value sets. A summary score is calculated by deducting all values of the 5 responses from the full mark of 1. A summary score of 1 represents perfect health, 0 represents death, below 0 represents a state being worse than dead. This summary score could be used for quality adjusted life-year (QALY) calculations. Thus EQ-5D is an important tool for economic valuation.  The EQ VAS lets the respondent place an “x” on a vertical VAS to reflect his/her self rated health. The endpoints are labeled ‘best imaginable health state’ at 100 and ‘worst imaginable health state’ at 0 |
| **Liver-cancer specific instruments** | |
| **European Organization for Research and Treatment of Cancer QLQ-HCC18** | EORTC QLQ-HCC18 includes eighteen multiple item scales organized into six domains (fatigue, body image, jaundice, nutrition, pain and fever) and two items (abdominal swelling and sex life)[24]. All scales are grouped and transformed to score ranging from 0 to 100. A lower score represents a less severe symptom/problem. EORTC QLQ-HCC18 is used together with EORTC QLQ-C30 |
| **Functional Assessment of Cancer Therapy-Hepatobiliary** | The FACT-Hep questionnaire is a 45-item instrument for measuring HRQOL in patients with hepatobiliary cancers (liver, bile duct and pancreas)[25]. FACT-Hep is used together with FACT-G. It consists of the 27 items (PWB, FWB, SFWB and EWB domains) in FACT-G together with an 18-item disease-specific hepatobiliary cancer subscale (HepCS) which address specific symptoms of hepatobiliary carcinoma, such as back/stomach pain, gastrointestinal symptoms, anorexia, weight loss, jaundice, as well as side-effects of treatment. An aggregate HepCS score could be obtained. The FACT-G and HepCS scores are summed to form the FACT-Hep total score. Higher scores on all scales of the FACT-Hep reflect better HRQOL or fewer symptoms |
| **Functional Assessment of Cancer Therapy-Hepatobiliary Symptom Index** | FHSI-8 is a subset of FACT-Hep. It includes eight items from the FACT-Hep that measure specific symptoms of patient priority concern and side effects of hepatobiliary carcinoma[26]. Higher scores on all items of the FHSI-8 reflect fewer symptoms |
| **Trial Outcome Index** | TOI is also a subset of FACT-Hep. It consists of the summation of the PWB, FWB and HepCS subscales[25]. Higher scores reflect better HRQOL and fewer symptoms |

EORTC QLQ-C30: European Organization for Research and Treatment of Cancer QLQ-C30; FACT-G: Functional Assessment of Cancer Therapy – General; QoL: Quality of Life; SF-36: Short Form 36; SF-12: Short Form 12; WHOQOL-100: World Health Organization Quality of Life Assessment 100; FACT-Hep: Functional Assessment of Cancer Therapy-Hepatobiliary; FHSI-8: Functional Assessment of Cancer Therapy - Hepatobiliary Symptom Index; TOI: Trial Outcome Index; HCC: Hepatocellular carcinoma; HRQOL: Health related quality of life.

**Table 3 Algorithm of C30 and HCC18 index scores**

|  |  |
| --- | --- |
| QOL Index scores for survival prognostication | |
| C30 index score | ∑ [(100-Physical functioning), (100-Role functioning), (100-Emotional functioning), (100-Cognitive functioning), (100-Social functioning), (100-global QOL), scores of Fatigue, Nausea/vomiting, Pain, Dyspnoea, Insomnia, Appetite loss, Constipation, Diarrhea, Financial Difficulty] ÷ 15 |
| HCC18 index score | ∑(scores of Fatigue, Body Image, Jaundice, Nutrition, Pain, Fever, Sex life, Abdominal distension) ÷ 8 |

QOL: Quality of life.